Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06818266 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06818266 · ClinicalTrials.gov record · last posted 2026-06-24

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

Study acronym: TOCIACS
StatusRecruiting
PhasePhase 3
Started2025-08-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2025-02-04; most recent amendment 2026-06-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-06-22
Status change Not Yet Recruiting→Recruitingv5
Trial Details
NCT Number NCT06818266
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Conditions Sickle Cell Disease, Acute Chest Syndrome
Enrollment 130 participants
Start Date 2025-08-27
Primary Completion 2027-04 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-24